Treatment of acute lymphoblastic leukemia in Hong Kong children: HKALL 93 study

Hematological Oncology

Volumn 21, Issue 1, 2003, Pages 1-9

  Li, C K ^a   Chik, K W ^a   Chan, G C F ^b   Yuen, H L ^c   Lee, A C W ^d   Li, C Keung ^e   Shing, M M K ^a   Ha, S Y ^b   Luk, C W ^c   Ling, S C ^e   Cheung, A Y K ^f  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^d TUEN MUN HOSPITAL   (Hong Kong)

^e PRINCESS MARGARET HOSPITAL   (Hong Kong)

^f CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

ALL; Children; Chinese

Indexed keywords

ASPARAGINASE; COTRIMOXAZOLE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; AGE; BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM; CHILD; CLINICAL PROTOCOL; CYTOGENETICS; DRUG MEGADOSE; FEMALE; HIGH RISK POPULATION; HONG KONG; HUMAN; IMMUNOPHENOTYPING; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SALVAGE THERAPY; TREATMENT OUTCOME;

ADOLESCENT; AGE FACTORS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HONG KONG; HUMANS; IMMUNOPHENOTYPING; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE; LOGISTIC MODELS; MALE; METHOTREXATE; PROGNOSIS; RECURRENCE; REGRESSION ANALYSIS; SALVAGE THERAPY; TIME FACTORS;

EID: 0037344068     PISSN: 02780232     EISSN: None     Source Type: Journal    
DOI: 10.1002/hon.698     Document Type: Review

References (19)

1. Li CK, Mang OWK, Foo W. Epidemiology of paediatric cancer in Hong Kong, 1982 to 1991. Hong Kong Cancer Registry. HKMJ 1999; 5: 128-134.
2. Pui CH, Boyett JM, Rivera GK, et al. Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia 2000; 14: 2286-2294.
3. Schrappe M, Reiter A, Zimmermann M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Leukemia 2000; 14: 2205-2222.
4. Gaynon PS, Trigg ME, Heerema NA, et al. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia 2000; 14: 2223-2233.
5. Silverman LB, Declerck L, Gelber RD, et al. Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995). Leukemia 2000; 14: 2247-2256.
6. Cave H, Ten Bosch JW, Suciu S, et al. for the European Organization for Research and Treatment of Cancer-Childhood Leukemia Cooperative Group. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. N Engl J Med 1998; 339: 591-598.
7. Coustan-Smith E, Sancho J, Hancock ML, et aI. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000; 96: 2691-2696.
8. Shing MMK, Li CK, Chik KW, et al. Outcomes and prognostic factors of Chinese children with acute lymphoblastic leukemia in Hong Kong: preliminary results. Med Pediatr Oncol 1999; 32: 117-123.
9. Ma SK, Chan GC, Ha SY, et al. Clinical presentation, hematologic features and treatment outcome of childhood acute lymphoblastic leukemia: a review of 73 cases in Hong Kong. Hematol Oncol 1997; 15: 141-149.
10. Yang CP, Lin ST, Liang DC, et al. Treatment of childhood acute lymphoblastic leukemia with protocol TCL-842 in Taiwan: the Taiwan Children's Cancer Study Group. J Formos Med Assoc 1993; 92: 431-439.
11. Chan LC, Ha SY, Ching LM, et al. Cytogenetics and immunophenotypes of childhood acute lymphoblastic leukemia in Hong Kong. Cancer Genet Cytogenet 1994; 76: 118-124.
12. Hann I, Vora A, Richards S, et al. On behalf of the UK Medical Research Council's Working Party on Childhood Leukaemia. Benefit of intensified treatment of all children with acute lymphoblastic leukaemia: results from MRC UKALL XI and MRC ALL97 randomised trials. Leukemia 2000; 14: 356-363.
13. Tsang KS, Li CK, Chik KW, et al. TEL/AML1 rearrangement and the prognostic significance in childhood acute lymphoblastic leukemia in Hong Kong. Am J Hematol 2001; 68: 91-98.
14. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996; 14: 18-24.
15. Abromowitch M, Ochs J, Pui CH, et al. High-dose methotrexate improves clinical outcome in children with acute lymphoblastic leukemia: St. Jude Total Therapy Study X. Med Pediatr Oncol 1988; 16: 297-303.
16. Schrappe M, Reiter A, Ludwig WD, et al. for the German-Austrian-Swiss ALL-BFM Study Group. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. Blood 2000; 95: 3310-3322.
17. Tubergen DG, Gilchrist GS, O'Brien RT, et al. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: A Childrens Cancer Group Phase III Trial. J Clin Oncol 1993; 11: 527-537.
18. Kaspers GJL, Veerman AJP, Popp-Snijders C, et al. Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. Med Pediatr Oncol 1996; 27: 114-121.
19. Nachman JB, Sather HN, Sensel MG, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 1998; 338: 1663-1671.